NCT02742623 - A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer | Biotech Hunter

Enrollment

528

Participants

Timeline

Start Date

October 11, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

March 28, 2019

Conditions

Venous Thrombosis and Pulmonary Embolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY 59-7939)

Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label

Trial Locations (10)

Multiple Locations